Cambridge scientists raise prospect of new generation of treatments after finding technique to limit development of biggest cause of dementia
Scientists have found a method which could potentially stop the growth of Alzheimer’s disease in its tracks, raising the prospect of a wave of new treatments for the condition.
A team at Cambridge University, working with partners in Sweden and Estonia, has identified a molecule which can block the progress of Alzheimer’s at a crucial stage in its development.
Not only is it the first time that experts have identified a means of breaking the cycle leading to the development of Alzheimer’s but they believe the technique could be used to identify other molecules as future treatments to curb the growth of the condition.
Charities hailed it as an “exciting” discovery.
More than 520,000 people in the UK are estimated to be living with Alzheimer’s, by far the most common cause of dementia.
Dementia-related conditions are already the biggest cause of death among women in Britain and only narrowly outranked by heart disease and cancer for men.
Alzheimer’s develops when proteins in the brain malfunction and then stick together into fibres. They in turn eventually form clusters called oligomers which are toxic to nerve cells.
The second stage of that process is believed to set off a chain reaction which multiplies the number of clusters, hastening the development of the most devastating effects.
Experts at the Centre for Misfolding Diseases in Cambridge’s Chemistry Department have identified that natural proteins called Brichos, can stick to the fibres preventing them merging with others and forming the damaging clusters, therefore limiting the effects.
They believe the method used could help them identify other so-called “chaperone molecules” which could attach themselves in a similar way raising the prospect of a new generation of treatments.
The Latest on: Chaperone molecules
via Google News
The Latest on: Chaperone molecules
- Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occon May 16, 2022 at 12:21 pm
Adding to previously reported overall functional and survival benefit data for AMX0035, these findings support effect of AMX0035 on disease progression in ALSRandomization to AMX0035 resulted in a ...
- Stem Cells’ Fate Depends on CAF-1’s Control over Chromatin Dynamicson May 2, 2022 at 5:06 am
This work is published in Nature Communications, in the paper, “Regulation of chromatin accessibility by the histone chaperone CAF ... precisely CAF-1 and other molecules sustain the genome ...
- Cancer Immunotherapy Developers in Asia Explore Diverse Approacheson May 1, 2022 at 11:56 pm
Most antibody-based cancer drugs target molecules that appear on the outer surfaces of cancer cells or are secreted by cancer cells. “Antibodies are generally believed to be too large to enter ...
- Amicus Therapeutics: An Inflection Point In Growthon April 27, 2022 at 4:12 pm
Operating out of Philadelphia Pennsylvania, Amicus is focused on the innovation and commercialization of "chaperone molecules" to treat rare (i.e., orphan) genetic diseases with correctable mutations.
- Trehalose Alleviates Polyglutamine-Mediated Pathology in a Mouse Model of Huntington Diseaseon April 14, 2022 at 5:01 pm
We next investigated the effects of the small molecules selected by the in vitro ... from transient overexpression of a molecular chaperone, HDJ-1 (ref. 13; Figure 1e). We also verified, by ...
- Molecular Biophysics: Titin, Actin, Myosinon August 18, 2020 at 10:11 am
Association of the chaperone alpha-B-crystallin with titin in heart muscle. J. Biol. Chem. 279:7917-7924. free pdf from publisher In the actomyosin in-vitro motility assay, fluorescently labeled actin ...
- Sahil Sharmaon August 17, 2020 at 10:17 pm
My doctoral thesis described the design and synthesis of heterocyclic molecules with antitubulin and xanthine ... which are present as multi-chaperone complexes in cancer cells and play a critical ...
- Targeting Hsp90on February 3, 2017 at 11:05 am
Hsp90 is a ‘molecular chaperone’ which cells rely on during the assembly ... The team identified a promising lead in family of small molecules, the pyrazole resorcinol series, and helped to ...
- Protein Targeting and Translocationon October 8, 2016 at 6:08 am
They follow an often complex pathway involving transient interaction with chaperone proteins, translocase components and phospholipid molecules, and after membrane insertion they may require assembly ...
- The Neal Rosen Lab: Research Overviewon August 26, 2016 at 4:50 pm
The laboratory is studying small molecules that selectively inhibit the components ... target in cancer patients is another major focus of our lab. Hsp90 is a chaperone required for maintaining the ...
via Bing News